Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice

The dystrophin-deficient, X-linked dystrophic mouse (mdx) was used to evaluate the efficacy of prednisolone treatment. A test protocol was used to take advantage of the quantifiable weakness and disability as well as molecular genetic defect shared with the X-linked Duchenne muscular dystrophy (DMD)...

Full description

Saved in:
Bibliographic Details
Published inResearch communications in chemical pathology and pharmacology Vol. 79; no. 1; p. 45
Main Authors Hudecki, M S, Pollina, C M, Granchelli, J A, Daly, M K, Byrnes, T, Wang, J C, Hsiao, J C
Format Journal Article
LanguageEnglish
Published United States 01.01.1993
Subjects
Animals
Calcium - metabolism
Fatigue - physiopathology
Mice
Mice, Inbred C57BL
Muscle Proteins - metabolism
Muscles - pathology
Muscles - physiopathology
Muscular Dystrophy, Animal - drug therapy
Muscular Dystrophy, Animal - genetics
Muscular Dystrophy, Animal - physiopathology
Physical Endurance - physiology
Prednisolone - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:The dystrophin-deficient, X-linked dystrophic mouse (mdx) was used to evaluate the efficacy of prednisolone treatment. A test protocol was used to take advantage of the quantifiable weakness and disability as well as molecular genetic defect shared with the X-linked Duchenne muscular dystrophy (DMD). Whole-body weakness and fatigue were determined by non-invasive force-transducer physiographic and variable-speed treadmill techniques, respectively. Other measurements included hind-limb muscle protein, calcium, and histomorphology. Subcutaneously-administered prednisolone elicited significant improvements in whole body strength throughout a two-month test period. Increases in strength were also accompanied by measurable increments in running endurance. In fact, prednisolone treatment appeared to protect mdx mice from the stressful effect of continuous running as determined by strength and muscle fiber diameter. Test results from this study support the limited therapeutic benefit observed previously in DMD patients treated with the glucocorticoid.
ISSN:0034-5164